Butterfly Network and the American College of Cardiology (ACC) have announced a collaboration on a clinical trial to use ultrasound technology for at-home scanning.
Butterfly announced the release of its next-generation ultrasound product, Butterfly iQ+, this week, which will be used in the trial. The system is described as a single-probe, whole-body ultrasound system with mobile device connectivity, featuring an integrated telemedicine platform.
“Our collaboration with the ACC will help us design clinical trials and care pathways for some of the more challenging heart diseases and accelerate the adoption of point-of-care ultrasound by cardiovascular clinicians,” said John Martin, Butterfly Network’s chief medical officer. “One of the key targets is heart failure, with a goal to radically change monitoring. If patients can assess their status at home via AI-guided lung scans with their clinician or care team remotely, we can avoid unnecessary and costly hospital visits. This will also provide patients with more timely intervention, improve quality of care, and improve their quality of life.”
“Through innovative collaborations like this—directly linking the technology and clinical worlds—the ACC aims to transform cardiovascular care and improve health outcomes,” said John Rumsfeld, ACC’s chief science and chief innovation officer. “The ACC will work in sync with Butterfly to help guide the scientific evaluation and clinical integration of point-of-care ultrasound in the management of cardiovascular conditions.”
“The ACC’s forward-thinking matches Butterfly’s disruptive and transformative innovation DNA. It’s been 71 years since its founding and the ACC is still setting the pace with the gold standard for heart health care,” said Laurent Faracci, Butterfly Network’s chief executive officer. “We’re thrilled to be working with the ACC to transform cardiovascular care together, especially in the critical area of congestive heart failure, for better care, better outcomes, and lower cost to all constituents.”